SCARB1 and triple-negative breast carcinoma: Studies conducted by Danilo et al. (2013) in MDA-MB-231 (triple negative breast cancer cells) have shown that pharmacological inhibition of SR-B1 (through BLT-1) or knockdown of SR-B1 resulted in a reduction in cell proliferation perhaps via a decreased activation of the Akt signaling pathway.